A266470 Stock Overview
BIOINFRA Life Science Inc., a healthcare company, develops cancer gene treatments and technologies that monitor the possibility of metastasis and recurrence in blood for cancer patients in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioInfra Life Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩278.00 |
| 52 Week High | ₩660.00 |
| 52 Week Low | ₩232.00 |
| Beta | 0 |
| 1 Month Change | -24.66% |
| 3 Month Change | -24.86% |
| 1 Year Change | -47.15% |
| 3 Year Change | -89.47% |
| 5 Year Change | n/a |
| Change since IPO | -93.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| A266470 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 3.0% | -2.1% | -3.0% |
| 1Y | -47.1% | -0.4% | 0.6% |
Return vs Industry: A266470 underperformed the KR Life Sciences industry which returned -0.4% over the past year.
Return vs Market: A266470 underperformed the KR Market which returned 0.6% over the past year.
Price Volatility
| A266470 volatility | |
|---|---|
| A266470 Average Weekly Movement | 14.2% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A266470's share price has been volatile over the past 3 months.
Volatility Over Time: A266470's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Dukyun Lee | www.bioinfra.co.kr |
BIOINFRA Life Science Inc., a healthcare company, develops cancer gene treatments and technologies that monitor the possibility of metastasis and recurrence in blood for cancer patients in South Korea. Its portfolio includes cancer screening test technology, cancer biomarker research, in-vitro diagnostics medical devices, and targeted drug delivery systems for cancer treatment. The company was founded in 2001 and is based in Seoul, South Korea.
BioInfra Life Science Inc. Fundamentals Summary
| A266470 fundamental statistics | |
|---|---|
| Market cap | ₩3.59b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A266470 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A266470 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A266470 perform over the long term?
See historical performance and comparison